Dr. Scott Rocklage entered his adult life by earning a B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from the Massachusetts Institute of Technology. It was while in this second institution that Rocklage had the privilege of conducting research in the laboratory of Nobel Prize winner, Richard Schrock. He has many years of leadership of medical companies. From 1990 to 1994 he served as president and CEO of Nycomed Salutar and then was the president founding CEO of Cubist Pharmaceuticals Inc. from 1994 to 2003.
He joined 5am Ventures in 2003 and was made its Managing Partner the following year. Under his leadership, Ventures has had three drugs FDA approved and put multiple drugs through clinical trials. In addition to his leadership at Ventures, he held man others at the same time. In 2004 he became the Board Chairman of Achaogen, serving in this capacity until 2015. also became Chairman of Novira Therapeutics, Inc. in 2012. He became Chairman of the Board of Cidara Therapeutics in 2013, a role he continues to hold. He has also been the CEO of Epirus Biopharmaceuticals, Inc. since 2016.
He had served as director of Pulmatrix, Inc. until just last year. Rocklage holds more than 30 patents for drugs he either an invented or co-invented. He lives and works in Boston, Massachusetts. From his home, he has written over 100 peer-reviewed articles. But his life in medical innovation is not nearly over. This past January 3, 2018, he became the founding investor and Chairman of the Board of Directors of Expansion Therapeutics. This company is leading the charge into researching cures for a wide range of genetic disorders.
It is particularly concentrated at the moment on finding cures for different kinds of muscular dystrophy. The company has some big-name investors, including several prominent medical research companies.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.